Top Markets
#1 Siren Siren +40.14%
#2 RedStone RedStone +24.77%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#4 Perle Perle +15.69%
#5 Ocean Protocol Ocean Protocol +15.26%
#6 KUB Coin KUB Coin +14.22%
#7 Verus Coin Verus Coin +13.51%
#8 Cysic Cysic +10.93%
#9 Nosana Nosana +10.32%
#10 Quack AI Quack AI +10.31%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.

VTGN
Classement en actions #31938
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Prix de l'action
$0.2619
Dernière synchronisation: 2026-08-17
Capitalisation boursière
$11.62M
Changement (1 jour)
-2.13%
Changement (1 an)
-92.30%
Pays
US
Échange VistaGen Therapeutics, Inc. (VTGN)

Catégorie

Healthcare
Revenus pour VistaGen Therapeutics, Inc. (VTGN)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de VistaGen Therapeutics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour VistaGen Therapeutics, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR